Date: 2012-11-26
Type of information: Fundraising
Company: Lanthio Pharma (The Netherlands)
Investors: Morphosys (Germany) BioGeneration Ventures (The Netherlands) INKEF Capital (The Netherlands) Hanzepoort
Amount: €4.8 million
Funding type: series A financing round
Planned used:
Others: Lanthio Pharma, a biopharmaceutical company focused on discovering and developing a new class of therapeutic peptides with high target selectivity and improved \"drug-like\" properties, has raised €4.8m in the first close of a Series A investment round by a syndicate led by BioGeneration Ventures and INKEF Capital that also included MorphoSys and Hanzepoort as investors. The Series A round will remain open for one additional investor.
This company is a spin-off of the University of Groningen. It has been launched in 2011 with seed funding from BioGeneration Ventures. It applies its proprietary lanthionine-peptide drug discovery technology LanthioPep™ for the generation of novel peptide therapeutics with increased resistance to peptidase degradation, high receptor specificity and increased intrinsic activity. Lanthio Pharma has generated stable, peptidase-resistant lanthionine peptides with highly specific agonistic activity for a number of GPCR targets, which is a focus area of the company. The LanthioPep™ technology includes a proprietary bacterial display library capability, which allows for the construction of focused or randomized libraries of up to 107 lanthionine-peptides. These libraries allow for immediate functional screening and easy production of peptides of interest for further in-vivo and in-vitro testing. Lanthio Pharma is now building a pipeline of therapeutic lantipeptides drugs. Its lead product is a lanthionine-stabilized specific agonist of the AT2 receptor, which has great potential in diseases where tissue protection is important, like fibrosis.
Therapeutic area:
